Galapagos NV Website

Galapagos NV

ENXTAM-GLPG

Company Overview

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

  • Name

    Galapagos NV

  • CEO

    Henry Gosebruch

  • Website

    www.glpg.com

  • Sector

    Biotechnology

  • Year Founded

    1999

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

What's happening

Nov 11, 2025 - Dec 11, 2025

Galapagos NV Faces Investor Caution Amid Strategic Shift and Mixed Analyst Sentiment

  • Galapagos NV presented promising Phase 2 data for its CD19 CAR T-cell therapy candidate, GLPG5101, showing a 100% objective response rate.
  • The company announced a strategic pivot away from cell therapies to focus on immunology and oncology, backed by €3 billion in cash reserves.
  • Analyst sentiment turned bearish during the month, with downgrades impacting investor confidence despite positive clinical developments.

Over the past month, Galapagos NV (GLPG) experienced a decline of 2.5%, underperforming relative to the S&P 500's modest gain of 0.3%. This period was marked by significant events that shaped investor sentiment and stock performance. Notably, GLPG showcased promising Phase 2 data from its ATALANTA-1 study at the American Society of Hematology annual meeting regarding its CD19 CAR T-cell therapy candidate, GLPG5101. The reported objective response rate reached an impressive 100%, with a complete response rate of 96% among heavily pretreated MCL patients; however, this positive news was overshadowed by the company's announcement to wind down its cell therapy activities.

The decision to shift focus away from cell therapies towards more concentrated efforts in immunology and oncology is part of a broader transformation strategy supported by substantial cash reserves totaling €3 billion. This strategic move aims to streamline operations while concentrating on areas perceived as having higher potential returns for investors. Despite these bullish developments within their pipeline candidates in CAR-T therapy, market reactions were tempered due to mixed analyst sentiments regarding GLPG's future prospects.

Research reports during this period reflected bearish sentiment toward GLPG’s stock performance. Wall Street Zen downgraded the company from "hold" to "sell," while Bernstein issued a new rating of "Market Perform." Analysts provided varying perspectives but generally leaned towards caution given recent downgrades alongside an average price target set at $31.33.

Overall market conditions also played a role in shaping perceptions around healthcare stocks; notably, Galapagos NV underperformed not only against the S&P but also against sector benchmarks—underperforming the Health Care (XLV) sector by -5.8%.

ENXTAM:GLPG